# A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

> **NCT06881992** · PHASE3 · RECRUITING · sponsor: **Rezolute** · enrollment: 16 (estimated)

## Conditions studied

- Tumor Hyperinsulinism (Tumor HI)

## Interventions

- **DRUG:** Ersodetug

## Key facts

- **NCT ID:** NCT06881992
- **Lead sponsor:** Rezolute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-16
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06881992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06881992, "A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06881992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*